Literature DB >> 772665

Trial of an oral antigen against upper respiratory-tract infection. Results in the second year (1973-74).

H C Price, G Henley.   

Abstract

A double-blind trial in two randomly structured groups of boarders (44 girls and 66 boys) aged 7 to 13 years was undertaken in two Bristrol schools. Dosage was 1 ml a day of fluid (antigen or placebo) orally for the first four weeks of the autumn term, absenteeism being the main parameter measured, using a structured recording code. There was a highly significant difference in the number of days lost from upper respiratory-tract infection in the treated as opposed to the placebo group (x2 = 40-00 P less than 0-001 (v = 1). The number of colds was also significantly lower in the treated group (x2 = 8-05 P less than 0-005 (V less than i)).

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 772665

Source DB:  PubMed          Journal:  Practitioner        ISSN: 0032-6518


  1 in total

1.  The bacterial lysate Lantigen B reduces the number of acute episodes in patients with recurrent infections of the respiratory tract: the results of a double blind, placebo controlled, multicenter clinical trial.

Authors:  Fulvio Braido; Giovanni Melioli; Piero Candoli; Andrea Cavalot; Mario Di Gioacchino; Vittorio Ferrero; Cristoforo Incorvaia; Carlo Mereu; Erminia Ridolo; Giovanni Rolla; Oliviero Rossi; Eleonora Savi; Libero Tubino; Giorgio Reggiardo; Ilaria Baiardini; Eddi di Marco; Gilberto Rinaldi; Giorgio Walter Canonica; Carlo Accorsi; Claudia Bossilino; Laura Bonzano; Michela DiLizia; Barbara Fedrighini; Valentina Garelli; Vincenzo Gerace; Sara Maniscalco; Ilaria Massaro; Alessandro Messi; Manlio Milanese; Silvia Peveri; Arminio Penno; Stefano Pizzimenti; Tiziana Pozzo; Alberto Raie; Sergio Regina; Francesca Sclifò
Journal:  Immunol Lett       Date:  2014-11-03       Impact factor: 3.685

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.